Cabozantinib may be cost effective in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news
FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
CT-guided renal ablation is safe for treating cancer in obese patients
CT-guided renal ablation is a safe and effective alternative to nephrectom...Read more on AuntMinnie.comRelated Reading:
AI could help radiologists better detect kidney cancer
Cryoablation comparable to surgery for kidney cancer
Do more CT scans lead to more kidney surgeries?
SPECT/CT can solve renal cell carcinoma diagnosis conundrum (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 24, 2021 Category: Radiology Source Type: news
Drug Improves Survival for Rare, Deadly Kidney Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 22, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, News, Source Type: news
Cabozantinib Improves Survival for Rare, Deadly Kidney Cancer
MONDAY, Feb. 22, 2021 -- The drug cabozantinib is more effective than two similar drugs, as well as the current standard treatment, in extending the lives of patients with a rare and deadly type of kidney cancer, according to a new study.
The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 22, 2021 Category: General Medicine Source Type: news
Drug Improves Survival for Rare, Deadly Kidney Cancer
Title: Drug Improves Survival for Rare, Deadly Kidney CancerCategory: Health NewsCreated: 2/22/2021 12:00:00 AMLast Editorial Review: 2/22/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 22, 2021 Category: Cancer & Oncology Source Type: news
Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
FRIDAY, Feb. 19, 2021 -- For first-line treatment of advanced renal cell carcinoma, progression-free and overall survival are significantly longer with lenvatinib plus pembrolizumab versus sunitinib, according to a study published online Feb. 13 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news
Combo Shows'Impressive' Survival Results in First-Line RCC Combo Shows'Impressive' Survival Results in First-Line RCC
The combination of lenvatinib and pembrolizumab outperformed sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC) in the CLEAR trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
"Silent" Mutation Linked to Worse Kidney Cancer Outcome
A synonymous mutation in the tumor suppressor gene BAP1 can result in loss of function of the protein without altering its amino acid sequence. (Source: The Scientist)
Source: The Scientist - February 17, 2021 Category: Science Tags: News & Opinion Source Type: news
Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
WEDNESDAY, Feb. 17, 2021 -- For adults with papillary renal cell carcinoma (PRCC), the dual vascular endothelial growth factor (VEGF)-MET (hepatocyte growth factor receptor) inhibitor cabozantinib improves progression-free survival (PFS), according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 17, 2021 Category: Pharmaceuticals Source Type: news
Cabozantinib Could Be New Standard for Papillary RCC Cabozantinib Could Be New Standard for Papillary RCC
Cabozantinib outperforms the current standard of care for renal cell carcinoma (RCC), according to results from the Southwest Oncology Group 1500 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Kidney cancer: A cluster of veins on your right testicle could be an early risk indicator
KIDNEY cancer: One in 34 males and one in 64 females will be diagnosed with kidney cancer in their lifetime warns Cancer Research. For men, noticing a cluster of veins on your right testicle could be an early sign. (Source: Daily Express - Health)
Source: Daily Express - Health - February 16, 2021 Category: Consumer Health News Source Type: news
MSK physician shares kidney cancer research at annual ASCO GU Symposium
(Memorial Sloan Kettering Cancer Center) Memorial Sloan Kettering's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 16, 2021 Category: International Medicine & Public Health Source Type: news
Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand
In a regulatory filing, Glenmark Pharma said it launched "SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP (maximum retail price) compared to the innovator brand, priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5 mg) per month". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 16, 2021 Category: Pharmaceuticals Source Type: news
Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer
(Dana-Farber Cancer Institute) Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2021 Category: Cancer & Oncology Source Type: news
